Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into ...

Gene therapy pioneer Jim Wilson and researcher Kiran Musunuru are using contrasting approaches to overcome “irrational ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $41.22, indicating a +0.12% change from the previous session's end. This change outpaced the S&P 500's 0.08% gain on the day. On the ...

Now, Johns Hopkins Medicine scientists say they have shed new light on how bacteria protect themselves from certain phage ...

Using CRISPR-based engineering methods to prompt stem cells to organize into embryo-like structures, scientists were able to create 'programmable' cellular models of embryos without ever experimenting ...

One of the key challenges of the modern genomics era is studying the thousands of genes in a single human cell at scale. To ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

University of Illinois at Urbana-Champaign researchers have developed a CRISPR-based diagnostic tool capable of detecting ...

A recent review published in the journal Engineering delves into the significant advancements and potential of CRISPR ...

Zurcher Kantonalbank Zurich Cantonalbank raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.0% in ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...